Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: The EVIDENCE study

Archives of Neurology

Volumn 62, Issue 5, 2005, Pages 785-792

  Schwid, Steven R ^a   Thorpe, John ^b   Sharief, Mohammad ^c   Sandberg Wollheim, Magnhild ^d   Rammohan, Kottil ^e   Wendt, Jeanette ^h   Panitch, Hillel ^f   Goodin, Douglas ^g   Li, David ⁱ   Chang, Peter ^j   Francis, Gordon ^j  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Tucson Neurology Associates   (United States)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j EMD SERONO INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA1A INTERFERON; METHYLPREDNISOLONE SODIUM SUCCINATE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INJECTION PAIN; INJECTION SITE REACTION; LEUKOCYTE DISORDER; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; SKIN NECROSIS;

EID: 20844456591     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.5.785     Document Type: Article

References (15)

1. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J Interferon Cytokine Res. 1998;18:967-975.
2. Stürzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. JInterferon Cytokine Res. 1999;19:1257-1264.
3. Rothuizen LE, Buclin T, Spertinei F, et al. Influence of Interferon β-1a dose frequency of PBMC cytokine secretion and biological effect markers. J Neuroimmunol. 1999;99:131-141.
4. IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
5. IFMB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
6. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
7. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol. 1999;46:197-206.
8. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56:1628-1636.
9. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly Interferon β-1a in relapsing MS. Neurology. 2002;59:1507-1517.
10. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59:1496-1506.
11. Panitch H. Differences between IFN beta-1A 44 meg TIW and 30 mcg QW sustained to 16 months: final EVIDENCE results [abstract]. Int J MS Care. 2003;5:80.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
13. Abdul-Ahad A, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1 a from mammalian cells. Cytokines Cell Mol Ther. 1997;3:27-32.
14. Munafo A, Trinchard-Lugan II, Nguyen TX, Buraglio M. Comparative bioavailability of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol. 1998;5:187-193.
15. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIM). Lancet. 2002;359:1453-1460.